Meropenem Acs Dobfar (Meropenem)

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections that require intravenous therapy.

• Complicated intra‑abdominal infections: provides bactericidal activity against mixed flora in patients with intra‑abdominal sepsis.
• Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens in complicated UTIs.
• Hospital‑acquired pneumonia: effective against multidrug‑resistant organisms causing nosocomial pneumonia.
• Ventilator‑associated pneumonia: treats ventilator‑related lung infections with high bacterial load.
• Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.
• Severe sepsis and septic shock: offers rapid bacterial clearance in critically ill patients.

• Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins (PBPs) across a wide range of Gram‑positive and Gram‑negative organisms. This binding disrupts the final transpeptidation step of peptidoglycan cross‑linking, leading to loss of cell wall integrity and bactericidal cell death. Its high affinity for multiple PBPs contributes to its broad‑spectrum activity and resistance to most β‑lactamases.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Infusion site phlebitis: pain or redness at the injection site.
• Elevated liver enzymes: transient increase in ALT/AST.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile infection: severe colitis following disruption of gut flora.
• Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction.
• Severe neutropenia: marked reduction in neutrophil count.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Severe allergic reactions: including Stevens‑Johnson syndrome.

Use meropenem with caution and observe clinical guidelines for high‑risk patients.

• Renal function: assess creatinine clearance and adjust dose in renal impairment.
• Allergy: avoid in patients with known hypersensitivity to carbapenems or β‑lactams.
• Seizure risk: monitor neurologic status in patients with CNS disorders or high doses.
• Superinfection: watch for fungal overgrowth or C. difficile colitis during prolonged therapy.
• Pregnancy: safety not established; prescribe only when benefit outweighs potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other drugs, requiring vigilance.

Major Interactions (Avoid)

• Valproic acid: meropenem reduces serum valproate levels, risking seizure breakthrough.
• Concurrent nephrotoxic agents (e.g., aminoglycosides): may exacerbate renal injury.
• Other carbapenems: combined use increases risk of neurotoxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: monitor renal function when used together.
• Warfarin: observe INR for potential anticoagulation changes.
• Oral contraceptives: efficacy may be reduced; advise alternative contraception.